Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Grand Theravac Life Science (Nanjing) Co. Ltd. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct examiners and 2 distinct art units. This indicates that the pending cases are being reviewed by different examiners in different specialized groups. The use of 2 distinct art units for the 2 pending office actions shows technical divergence in the company's current patent applications.
SAIDHA, TEKCHAND is the busiest examiner for the company. This examiner is responsible for 1 pending office action. Because there are 2 distinct examiners for 2 pending actions, the workload is distributed across the examination staff. This distribution between actions, examiners, and art units means that matters are being prosecuted in unique environments within the patent office. Practitioners must develop strategies for each case to account for the different technical standards of the 2 distinct art units and the individual approaches of the 2 distinct examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAIDHA, TEKCHAND | 1 | 82.9% | +14.1% |
| BOESEN, AGNIESZKA | 1 | 68.5% | +21.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18720596 | WHOOPING COUGH ANTIGEN RECOMBINANT EXPRESSION VECTOR, AND ENGINEERED STRAIN AND USE THEREOF | SAIDHA, TEKCHAND | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18259893 | NOROVIRUS VIRUS-LIKE PARTICLE, IMMUNE COMPOSITION, OR KIT, AND USE THEREOF | BOESEN, AGNIESZKA | 70d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18259893 | NOROVIRUS VIRUS-LIKE PARTICLE, IMMUNE COMPOSITION, OR KIT, AND USE THEREOF | BOESEN, AGNIESZKA | 70d |
| 18720596 | WHOOPING COUGH ANTIGEN RECOMBINANT EXPRESSION VECTOR, AND ENGINEERED STRAIN AND USE THEREOF | SAIDHA, TEKCHAND | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18720596 | WHOOPING COUGH ANTIGEN RECOMBINANT EXPRESSION VECTOR, AND ENGINEERED STRAIN AND USE THEREOF | SAIDHA, TEKCHAND | 1652 | §112 | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18259893 | NOROVIRUS VIRUS-LIKE PARTICLE, IMMUNE COMPOSITION, OR KIT, AND USE THEREOF | BOESEN, AGNIESZKA | 1672 | §103§112 | Final Rejection | 70d | Pending | Jun 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial